Cartesian rises on FDA's 'RMAT' tag for autoimmune disease treatment

Cartesian Therapeutics

22/05/2024 14:57

** Shares of cell therapy developer Cartesian Therapeutics
 RNAC.O  rise ~8.3% to $26.64
    ** Company says U.S. FDA has granted regenerative medicine
advanced therapy (RMAT) designation for its CAR-T cell therapy,
Descartes-08, for the treatment of myasthenia gravis
    ** Myasthenia gravis is an autoimmune condition that causes
skeletal muscle weakness
    ** RMAT designation expedites development and review of
regenerative medicine therapies and offers sponsor companies
early interactions with FDA
    ** Including session's move, stock up ~28.1% YTD
    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))